Elite neutralizers of human cytomegalovirus are characterized by high magnitude plasma IgG responses against multiple glycoprotein complexes

Background. Human cytomegalovirus (HCMV) is the most common infectious complication of organ transplantation and cause of birth defects worldwide. There are limited therapeutic options and no licensed vaccine to prevent HCMV infection or disease. To inform development of HCMV antibody-based interventions, a previous study identified individuals with potent and broad plasma HCMV-neutralizing activity, termed elite neutralizers (EN), from a cohort of HCMV-seropositive (SP) blood donors. Yet, the specificities and functions of plasma antibodies associated with EN status remained undefined. Methods. We sought to determine the plasma antibody specificities, breadth, and Fc-mediated antibody effector functions associated with the most potent HCMV-neutralizing responses in plasma from EN (n=25) relative to SP (n=19). We measured antibody binding against various HCMV strains and glycoprotein targets, and evaluated Fc-mediated effector functions, antibody dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP). Results. We demonstrate that elite HCMV neutralizers have elevated IgG binding responses against multiple viral glycoproteins, relative to SP. Our study also revealed potent HCMV-specific ADCC and ADCP activity of EN plasma, Conclusions. We conclude that antibody responses against multiple glycoprotein specificities may be needed to achieve potent plasma neutralization and that potently HCMV elite-neutralizing plasma antibodies can also mediate polyfunctional responses.


65
have been highlighted as potentially protective against HCMV infection. [11,12] 66 67 Glycoprotein B (gB) has been a central focus of HCMV vaccine efforts due to its high abundance, CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted June 7, 2022. ; https://doi.org/10.1101/2022.06.06.22275103 doi: medRxiv preprint 4 (gH/gL) exists as part of the PC, but also associates with other glycoproteins, including gO and 78 gB. [19,20] Antibodies that are specific for the gH/gL and gH/gL/gO complexes have been shown 79 to block HCMV infection in vitro, suggesting that they may also be protective [21]. Yet, it is non-neutralizing responses, such as virion phagocytosis, but elicited poor neutralization 95 responses and antibodies with limited ability to neutralize heterologous HCMV strains. [11,33] 96 Moreover, IgG binding to gB expressed on the cell surface was identified as a potential immune 97 correlate of protection associated with the risk of infection across two gB/MF59 vaccine trials, 98 indicating the importance of glycoprotein conformation in effective antibody immunity. [34] There 99 is considerable interest in advancing our understanding of protective anti-HCMV antibody 100 specificities in natural infection to guide vaccine and therapeutic antibody development.

101
102 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted June 7, 2022.

128
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted June 7, 2022.

180
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted June 7, 2022.

199
To determine differences between EN and SP antibody responses against HCMV, plasma IgG 200 binding to TB40/E, AD169r, and Towne whole virus was measured by ELISA. These viruses were 201 selected based on glycoprotein B genotype and differences in PC expression (listed in Table 1).

202
EN plasma exhibited significantly higher IgG binding to all tested strains, relative to SP controls 203 (all p<0.0001) ( Fig 1A). Next, we explored whether EN and SP individuals differed in terms of time 204 since primary infection or re-infection by measuring HCMV-specific plasma IgG avidity and IgM 205 binding responses. EN exhibited a significant increase in IgG avidity for AD169r (p=0.004), but 206 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted June 7, 2022. ; https://doi.org/10.1101/2022.06.06.22275103 doi: medRxiv preprint no statistically significant differences in avidity for TB40/E (p=0.09) or Towne (p=0.07), relative to 207 SP controls (Fig 1B). Additionally, while the proportion of EN with detectable plasma HCMV 208 TB40E-specific IgM was higher than that of SP (78.6.0% vs 21.4%, respectively), this difference 209 was not statistically significant as determined by Fisher Exact Test (FDR p-value=0.07) (Fig 1C).   genotypes (all p<0.0001) relative to SP controls (Fig. 3 A and B). We then assessed plasma IgG 231 binding breadth by calculating the number of gB genotypes bound by each plasma sample using 232 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted June 7, 2022.

258
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted June 7, 2022. ; https://doi.org/10.1101/2022.06.06.22275103 doi: medRxiv preprint plasma to promote HCMV-specific ADCP and ADCC in flow-based assays using whole HCMV 259 virions and HCMV-infected fibroblasts, respectively. Using a linear regression model, we 260 determined that EN plasma exhibited significantly enhanced ability to promote ADCP of the whole 261 HCMV virion and ADCC responses against infected cells, relative to SP (p<0.0001 and p=0.01, 262 respectively) (Fig. 4A and 4B). However, after adjusting for total HCMV-specific IgG concentration 263 in the linear regression model, the ADCC and ADCP responses did not differ between EN and 264 SP groups (Table 3).

267
In this study, we found that EN plasma can mediate potent HCMV-specific polyfunctional 268 responses, including neutralizing and non-neutralizing effector functions. We observed 269 significantly elevated HCMV-specific IgG binding responses to three strains of HCMV and higher 270 avidity for AD169r among EN plasma, relative to that of SP. Moreover, we found that EN plasma  CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted June 7, 2022.

288
After normalizing HCMV glycoprotein-specific IgG concentrations by total HCMV-specific IgG 289 concentration, we observed that EN plasma maintains significantly elevated binding responses 290 against all targets, except for gB genotype 2, relative to SP. Interestingly, our correlative analysis 291 of normalized responses revealed a negative correlation between plasma IgG against neutralizing 292 epitope gB AD2S1 and gB genotype 2, but only among EN (Supplementary Figure 2). One 293 potential explanation is that although AD2S1 is known to be highly conserved across genotypes, 294 sequence variations in nearby residues may conformationally shield AD2S1 in gB genotype 2 and 295 disrupt antibody binding to this site and that, relative to SP, a larger proportion of gB-specific 296 antibodies in EN plasma is directed towards this neutralizing epitope. Moreover, the differences 297 observed between EN and SP binding to cell-associated gB could indicate that EN plasma 298 contains antibodies specific for unique epitopes of gB that are exposed when gB is associated 299 with the cell surface, which was previously identified as a correlate of protection in the gB/MF59 300 vaccine trials [34]. Overall, our findings indicate that incorporating multiple glycoprotein B  Finally, we observed that EN plasma exhibits significantly elevated neutralization against HCMV 308 relative to SP, even after adjusting for total HCMV-specific IgG concentration. Thus, neutralizing 309 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted June 7, 2022. ; https://doi.org/10.1101/2022.06.06.22275103 doi: medRxiv preprint 13 status does not appear to be determined solely by the magnitude of the HCMV-specific antibody 310 titer, but rather by the quality and specificities of HCMV-specific antibodies generated in response 311 to infection. Interestingly, this was not observed for the HCMV Merlin (gB1) strain, which has been 312 characterized as potentially more representative of clinical isolates than some lab-adapted strains 313 [49]. Yet, while EN plasma was also capable of mediating significantly higher magnitudes of 314 ADCP and ADCC relative to SP, these responses did not distinguish between groups after 315 adjusting for HCMV-specific IgG in a linear regression model. This suggests that unlike the distinct 316 quality of HCMV-neutralizing responses between EN and SP individuals, differences in ADCP 317 and ADCC response magnitudes between groups are due to the higher HCMV-specific IgG 318 concentration in EN plasma, not a distinction in antibody response quality.

320
There are several limitations to this study. First, the sample size is relatively low, and all plasma 321 samples were selected from blood donors at a single timepoint. This study was designed as a 322 cross-sectional study, so our results cannot definitively confirm acute versus chronic infection 323 within the cohort. Interestingly, while the proportion of HCMV-specific IgM responses was higher 324 in EN, the difference was not statistically significant between groups. We cannot rule out that IgM 325 responses are contributing to EN status, but our IgM binding and IgG avidity data suggest that 326 time since primary infection or re-infection is not distinct between EN and SP. Therefore, the 327 higher neutralization capacity observed among EN plasma is likely not solely attributable to a 328 recent primary HCMV infection. Additionally, due to limited sample volume, we were unable to

384
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted June 7, 2022.  is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted June 7, 2022.   CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted June 7, 2022.  CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted June 7, 2022.  is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted June 7, 2022.

503
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted June 7, 2022.

527
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted June 7, 2022. ; https://doi.org/10.1101/2022.06.06.22275103 doi: medRxiv preprint